Signaling pathways
- BA2315 PolatuzumabSummary: Polatuzumab is a monoclonal antibody with a chemotherapeutically active molecule.
- BA2316 InotuzumabSummary: Inotuzumab (HumanizedAnti-CD22RecombinantAntibody) is humanized, κ-antibody targeted to humans.
- BA2317 IzeltabartSummary: Izeltabart is a high affinity humanized antibody that targets.
- BA2318 LifastuzumabSummary: Lifastuzumab is a humanized anti-monoclonal antibody (IgG1 type).
- BA2319 BriobaceptSummary: Briobacept (BR3FC) is a selectively targeted monoclonal antibody that induces apoptosis in B cells.
- BA2320 DxdSummary: Dxd (ExatecanderivativeforADC) is a potent inhibitor.
- BA2321 MertansineSummary: Mertansine (DM1) is an inhibitor and an antibody-conjugatable medetomidine alkaloid used to overcome the systemic toxicity associated with medetomidine and to enhance tumor-specific delivery.
- BA2322 ExatecanSummary: Exatecan (DX-8951) is a DNA topoisomerase I inhibitor.
- BA2323 DM4Summary: DM4 is an anti-microtubule protein agent that inhibits cell division.
- BA2324 SG3199Summary: SG3199 is a cytotoxic DNA minor groove interstrand cross-linked PBD dimer.